All articles tagged with #shingrix
A large observational study in Nature Medicine finds that the recombinant shingles vaccine Shingrix is associated with a 9% lower cardiovascular burden over seven years compared to the older Zostavax vaccine. Researchers suggest this could prevent hundreds of thousands of heart events globally if confirmed, though causality is not yet proven.
A large observational study in the US found that switching from the live-attenuated shingles vaccine to the recombinant Shingrix vaccine was associated with a 9% lower burden of cardiovascular disease over seven years. The study, published in Nature Medicine, used a natural experiment design to mitigate bias, showing reduced risks for heart failure and ischemic heart disease. While the absolute risk reduction is small, the potential population impact is significant, prompting calls for randomized trials to confirm causality.
A new study published in Nature Medicine suggests that the recombinant shingles vaccine, Shingrix, is associated with a 9% lower risk of cardiovascular disease over seven years compared to the older live vaccine, Zostavax. The findings indicate reduced risks for heart failure, ischemic heart disease, and stroke in men. Experts caution that the study shows an association, not causation, and that the vaccine should not replace standard heart health measures.
A large US study finds that the switch to the recombinant shingles vaccine Shingrix is associated with a 9% lower burden of cardiovascular disease over seven years compared to the older live-attenuated vaccine. While the findings suggest potential benefits for heart health and dementia, experts emphasize these are observational associations, not proof of causation, and further trials are needed.
New research suggests the recombinant shingles vaccine, Shingrix, may reduce risks of dementia and cardiovascular disease in older adults. A Brown University study found a 24% lower dementia risk, while a Nature Medicine study linked the vaccine to a 9% lower cardiovascular burden compared to older vaccines. Experts emphasize these are associations, not proof of causation, and note the vaccine’s primary purpose remains preventing shingles.
Neurologist Dr. Ajeet Sodhi explains that while some research links the shingles vaccine to a lower dementia risk, the findings show an association rather than proof of causation, and more studies are needed to establish any definitive protective effect.
A large US study finds that the recombinant shingles vaccine, Shingrix, is associated with a significant reduction in cardiovascular disease risk for older adults. By comparing vaccinated cohorts before and after the vaccine's rapid adoption in 2017, researchers found a 9% decrease in cardiovascular burden over seven years. The protective effect was most pronounced for ischemic heart disease and heart failure, suggesting the vaccine may offer benefits beyond preventing shingles.
A new study published in Nature Medicine finds that the recombinant shingles vaccine (Shingrix) is associated with a 9% lower risk of cardiovascular events over seven years compared to the older live-attenuated vaccine. The findings suggest potential cardioprotective benefits beyond shingles prevention, though researchers emphasize that causation is not yet proven and further clinical trials are needed.
A new study suggests that the Shingrix shingles vaccine may reduce the risk of heart attacks, strokes, and heart failure by 9% over seven years. Published in Nature Medicine, the research analyzed records of 72,000 US adults aged 60 and older. By comparing those vaccinated before and after the 2017 switch from the older Zostavax vaccine to Shingrix, researchers found a significant drop in cardiovascular events. While the absolute risk reduction is small, the potential population-wide impact is substantial. Experts believe the vaccine's adjuvant may reduce inflammation, though randomized trials are needed to confirm causation.
GSK is launching a large study to determine whether the shingles vaccine Shingrix can lower dementia risk, prompted by observational data suggesting vaccinated individuals may have fewer dementia cases; the trial aims to establish causality and could influence dementia prevention strategies if results are favorable.
New research across the U.S. and other countries finds that receiving the shingles vaccine—especially Shingrix—might lower dementia risk in older adults by reducing brain inflammation, though most studies are observational and benefits vary by sex and prior vaccination; vaccination rates are still low despite potential protection.
A Brown University-led analysis of more than 500,000 Medicare beneficiaries found that older adults who received the Shingrix shingles vaccine after entering skilled nursing facilities had about 24% fewer dementia diagnoses over four years compared with those unvaccinated, though the study cannot prove causation and residual differences between groups may influence results.
A real-world study of 509,926 nursing‑facility residents found that those who received the Shingrix shingles vaccine within 12 months of admission had a 24% lower risk of developing dementia over four years than unvaccinated peers, though the observational design cannot establish causation. Uptake was low (8,843 vaccinated), and researchers note potential neuroinflammatory mechanisms and confounders; the study was funded by GlaxoSmithKline, and Shingrix’s real‑world cognitive benefits add to questions about why vaccines might protect brain health.
A large U.S. Medicare study (1.5 million beneficiaries) found that older adults who received the two-dose recombinant zoster vaccine (Shingrix) had a lower incidence of dementia than unvaccinated peers, with about a 28–33% reduced risk for any dementia, Alzheimer's disease, and vascular dementia over up to three years and continued protection beyond three years; results are observational and can’t prove causality, but align with other real-world evidence and call for trials to confirm.
Ars Technica, citing The New York Times, reports that the FDA blocked publication of studies on COVID-19 and Shingrix vaccines showing benefits; the CDC reportedly scrapped a separate vaccine study. HHS says withdrawals protected scientific integrity, but critics frame the moves as censorship connected to RFK Jr.’s anti-vaccine agenda under his health department.